Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
CYT003-QbG10 × 1 year × Clear all
NCT04387071 2026-04-17

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

University of Southern California

Phase 1/2 Terminated
2 enrolled 15 charts
Gastrointestinal

Pancreatic Neoplasms

NCT05445609 2025-09-19

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Emory University

Phase 2 Suspended
10 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡